5 research outputs found
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. 2022, The Author(s).The authors would like to thank all the patients, volunteers, and the healthcare co-workers from Allergy and Immunology Section-HMC, and Dr. Mohamed G.H. Mohamedali, Mr. Hassen Maatoug, and Mr. Ahmed Soliman from Hezm Mebairek General Hospital-HMC for developing disposable racks for samples transportation, tubes labeling, blood collection, and handling. We thank the support provided by Qatar University Biomedical Research Centre, Biosafety Level 3, and Associate Professor Hadi M. Yassine (M.Sc., Ph.D.). We also acknowledge the help of the Anti-Doping Lab-Qatar (ADLQ) and Qatar Red Crescent (QRC) for recruiting control samples. This work was supported by a grant fund from Hamad Medical Corporation (fund number MRC-05-003) and core funding from Qatar Biomedical Research Institute (QBRI).Scopu
Recommended from our members
Programming human pluripotent stem cells into white and brown adipocytes
The utility of human pluripotent stem cells is dependent on efficient differentiation protocols that convert these cells into relevant adult cell types. Here we report the robust and efficient differentiation of human pluripotent stem cells into white or brown adipocytes. We found that inducible expression of PPARG2 alone or combined with CEBPB and/or PRDM16 in mesenchymal progenitor cells derived from pluripotent stem cells programmed their development towards a white or brown adipocyte cell fate with efficiencies of 85%–90%. These adipocytes retained their identity independent of transgene expression, could be maintained in culture for several weeks, expressed mature markers and had mature functional properties such as lipid catabolism and insulin-responsiveness. When transplanted into mice, the programmed cells gave rise to ectopic fat pads with the morphological and functional characteristics of white or brown adipose tissue. These results indicate that the cells could be used to faithfully model human disease.Stem Cell and Regenerative Biolog
Human Induced Pluripotent Stem Cells as an In Vitro model for Human Cardiomyocytes to Study Maturation and Metabolism
This project aimed to generate a mature population of human induced pluripotent stem cell
derived cardiomyocytes (hiPSC-CM) which would have the metabolic phenotype of
cardiomyocytes in the adult heart as metabolic disorders are strongly linked with
cardiovascular disease. Two published differentiation protocols were assessed, and the
Wnt-modulation protocol was chosen as it upregulated the gene expression of cardiac
genes. In addition, after introducing some alterations, such as transient hypoxia and the
addition of Activin A, spontaneously beating human induced pluripotent stem cell derived
cardiomyocytes (hiPSC-CMs) were generated.
We characterised the changes in substrate metabolism after differentiation and showed that
as hiPSCs are differentiated into beating hiPSC-CMs, there was an increase in both
glycolysis and fatty acid oxidation, associated with changes in mRNA expression of
glucose and fatty acid metabolism genes. Addition of a PPAR-α agonist (WY14643) to
hiPSCs during differentiation did not induce changes in gene expression or substrate
metabolism, however addition of the agonist in combination with oleic acid to beating
hiPSC-CMs upregulated fatty acid oxidation and respiratory reserve capacity.
Interestingly, in beating hiPSC-CM, the addition of oleic acid alone upregulated pyruvate
oxidation but not that of oleic acid. There was no change in glycolytic flux with either
treatment, suggesting that although activation of PPAR-α increased the capacity of the cells
for fatty acid oxidation, they could generate sufficient energy from the high glucose in the
culture medium via glycolysis.
In conclusion, as hiPSC-CMs are differentiated there is an upregulation in both glycolysis
and fatty acid oxidation. This maturation of metabolism can be further enhanced when PPAR-α is activated using WY14643 in the presence of fatty acids. This provides a method
to metabolically mature hiPSC-CMs, so that they more closely resemble mature
cardiomyocytes.</p
Islets in the body are never flat: transitioning from two-dimensional (2D) monolayer culture to three-dimensional (3D) spheroid for better efficiency in the generation of functional hPSC-derived pancreatic β cells in vitro
Abstract Diabetes mellitus (DM), currently affecting more than 537 million people worldwide is a chronic disease characterized by impaired glucose metabolism resulting from a defect in insulin secretion, action, or both due to the loss or dysfunction of pancreatic β cells. Since cadaveric islet transplantation using Edmonton protocol has served as an effective intervention to restore normoglycaemia in T1D patients for months, stem cell-derived β cells have been explored for cell replacement therapy for diabetes. Thus, great effort has been concentrated by scientists on developing in vitro differentiation protocols to realize the therapeutic potential of hPSC-derived β cells. However, most of the 2D traditional monolayer culture could mainly generate insulin-producing β cells with immature phenotype. In the body, pancreatic islets are 3D cell arrangements with complex cell–cell and cell–ECM interactions. Therefore, it is important to consider the spatial organization of the cell in the culture environment. More recently, 3D cell culture platforms have emerged as powerful tools with huge translational potential, particularly for stem cell research. 3D protocols provide a better model to recapitulate not only the in vivo morphology, but also the cell connectivity, polarity, and gene expression mimicking more physiologically the in vivo cell niche. Therefore, the 3D culture constitutes a more relevant model that may help to fill the gap between in vitro and in vivo models. Interestingly, most of the 2D planar methodologies that successfully generated functional hPSC-derived β cells have switched to a 3D arrangement of cells from pancreatic progenitor stage either as suspension clusters or as aggregates, suggesting the effect of 3D on β cell functionality. In this review we highlight the role of dimensionality (2D vs 3D) on the differentiation efficiency for generation of hPSC-derived insulin-producing β cells in vitro. Consequently, how transitioning from 2D monolayer culture to 3D spheroid would provide a better model for an efficient generation of fully functional hPSC-derived β cells mimicking in vivo islet niche for diabetes therapy or drug screening. Video Abstrac
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.</div